Orphan drug Designation for Anti-Pseudomonas IgY

Swedish biotech company IMMUNSYSTEM I.M.S. AB announces that the European Medicines Agency, EMEA, has granted an orphan drug designation to the drug candidate Anti-Pseudomonas IgY for use in the treatment of cystic fibrosis.

For questions regarding treatment of cystic fibrosis, please contact Hans Kollberg, professor emeritus, MD,PhD, project leader for Anti-pseudomonas IgY, Immunsystem, I.M.S. AB, Sweden. Hans.kollberg@kbh.uu.se.

Orphan drug announcement

Read the announcement (English)

Anti-Pseudomonas IgY

Immunotherapy with IgY is by design a low toxicity treatment and is therefore ideally suited for long term prophylaxis, even more so for conditions where it is simply not possible to stay away from the microorganisms that cause the infection.

Read more >>

Cystic Fibrosis

Cystic fibrosis is one of the most common life-shortening, childhood-onset inherited diseases and in caucasian populations, it is the most common life-shortening genetic disease.

Read More >>